280 results
424B3
PRTG
Portage Biotech Inc
12 Apr 24
Prospectus supplement
5:22pm
, including without limitation, statements about the Company that are forward-looking in nature and, business strategy, plans and objectives
6-K
EX-99.1
PRTG
Portage Biotech Inc
12 Apr 24
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
5:21pm
of historical facts, including without limitation, statements about the Company that are forward-looking in nature and, business strategy, plans
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
other pre-tax items of income and expense were substantially non-cash in nature and aggregated to approximately $44.9 million net expense in the Fiscal
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
. NATURE OF OPERATIONS
Portage Biotech Inc. (the “Company” or “Portage”) is incorporated in the British Virgin Islands (“BVI”) with its registered office …
Nature of Operations and Overview
Summary of Results
Number of Ordinary Shares
Business Environment – Risk Factors
Our Programs and Technology
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
dated February 28, 2024)
NOTE 1. NATURE OF OPERATIONS
Portage Biotech Inc. (the “Company” or “Portage”) is incorporated in the British Virgin Islands
6-K
EX-99.2
k9lb6fupsaayo3futp9
28 Feb 24
Current report (foreign)
5:17pm
424B3
fuxdl6xg2ylxwi
4 Jan 24
Prospectus supplement
5:49pm
6-K
EX-99.1
ri23066eynmbp59b
4 Jan 24
Current report (foreign)
8:10am
424B3
hhg4cij 2g5rm
28 Nov 23
Prospectus supplement
4:03pm
6-K
EX-99.1
igd86pfc jyxj
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
6-K
EX-99.1
b50hvz
28 Nov 23
Current report (foreign)
4:01pm
6-K
EX-99.2
b4n9rrwbddc5kn h5
28 Nov 23
Current report (foreign)
4:01pm
424B3
01iqk9sc
7 Nov 23
Prospectus supplement
4:50pm
F-1
0oa8v
31 Oct 23
Registration statement (foreign)
4:05pm
D
6rbbazyz
13 Oct 23
$1.00 in options / securities to be acquired, sold $1.00, 1 investor
6:03pm
6-K
EX-10.1
27w2k w1hrpw5nkg1cp3
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-5.2
xeteukhkadqr49crr9sr
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-5.1
qi4 6pfpyw0d2r2uz
3 Oct 23
Current report (foreign)
4:05pm
424B5
fz12hoxdf8
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
lf9c6it49p0 9yd6
29 Sep 23
Portage Biotech Announces $6.0 Million Registered Direct Offering
8:01am